A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder.
This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population.
McRae-Clark
Aimee L
AL
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, USA. mcraeal@musc.edu
Carter
Rickey E
RE
Killeen
Therese K
TK
Carpenter
Matthew J
MJ
White
Kathleen G
KG
Brady
Kathleen T
KT
D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy*; D017831:Diagnosis, Dual (Psychiatry); D004311:Double-Blind Method; D058999:Drug-Seeking Behavior / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D002189:Marijuana Abuse / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D010919:Placebos; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use*; D057566:Self Report
D018759:Adrenergic Uptake Inhibitors; D010919:Placebos; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride